<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217161</url>
  </required_header>
  <id_info>
    <org_study_id>HS# 2019-5585</org_study_id>
    <nct_id>NCT04217161</nct_id>
  </id_info>
  <brief_title>Dexcom G6 Continuous Glucose Monitoring in Hemodialysis</brief_title>
  <acronym>DEXCOM-HD</acronym>
  <official_title>Comparison of Dexcom G6 Continuous Glucose Monitoring System and Blood Glucose Levels in Adult Hemodialysis Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the
      University of California Irvine Medical Center (UCIMC) who will undergo simultaneous
      measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom
      G6 device vs. 2) &quot;gold-standard&quot; blood glucose levels using capillary fingerstick or venous
      blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study
      will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood
      glucose measurements in the study population.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose measurement</measure>
    <time_frame>3 to 5 days</time_frame>
    <description>Proportion of CGM values within 20% of blood glucose levels &gt;100 mg/dl or within 20 mg/dl of blood glucose level for levels &lt;=100 mg/dl. (Will examine different thresholds of CGM values within a certain range of blood glucose levels, i.e., 10%, 15%, 25%.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia events</measure>
    <time_frame>3 to 5 days</time_frame>
    <description>Comparison in number of hypoglycemia events (glucose &lt;70 mg/dl) determined by CGM or by blood glucose measurements</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes</condition>
  <condition>Hemodialysis</condition>
  <condition>Glucose Measurement</condition>
  <arm_group>
    <arm_group_label>Dexcom G6 Continuous Glucose Monitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexcom G6 Continuous Glucose Monitor</intervention_name>
    <description>Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement</description>
    <arm_group_label>Dexcom G6 Continuous Glucose Monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Adult hemodialysis patients age 18 years or older; 2) have a comorbidity of diabetes; 3)
        receipt of care from the inpatient University of California Irvine Medical Center
        nephrology consult service; 4) expected hospital stay â‰¥48 hours; and 5) have the ability to
        directly provide informed consent for participation in the study.

        Exclusion Criteria:

        1) Critically-ill patients receiving care in the intensive care unit (ICU) or cardiac care
        unit (CCU), 2) moribund patients expected to die within 48 hours, 3) presence of any
        condition deemed by PI's judgment that would seriously limit life expectancy (i.e., poor
        survival), 4) pregnant, and 5) unwilling or unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Connie Rhee, MD, MSc</last_name>
    <phone>714-456-5142</phone>
    <email>crhee1@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamyar Kalantar-Zadeh, MD, MPH, PhD</last_name>
    <phone>714-456-5142</phone>
    <email>kkz@uci.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Rhee CM, Kovesdy CP, Ravel VA, Streja E, Brunelli SM, Soohoo M, Sumida K, Molnar MZ, Brent GA, Nguyen DV, Kalantar-Zadeh K. Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes. Diabetes Care. 2017 Aug;40(8):1050-1057. doi: 10.2337/dc17-0110. Epub 2017 Jun 7.</citation>
    <PMID>28592525</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Kovesdy CP, Ravel VA, Streja E, Sim JJ, You AS, Gatwood J, Amin AN, Molnar MZ, Nguyen DV, Kalantar-Zadeh K. Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis. J Ren Nutr. 2019 Mar;29(2):82-90. doi: 10.1053/j.jrn.2018.07.003. Epub 2018 Nov 15.</citation>
    <PMID>30448393</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Kovesdy CP, You AS, Sim JJ, Soohoo M, Streja E, Molnar MZ, Amin AN, Abbott K, Nguyen DV, Kalantar-Zadeh K. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. Am J Kidney Dis. 2018 Nov;72(5):701-710. doi: 10.1053/j.ajkd.2018.04.022. Epub 2018 Jul 20.</citation>
    <PMID>30037725</PMID>
  </reference>
  <reference>
    <citation>Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014 Mar;27(2):135-45. doi: 10.1111/sdi.12198. Review.</citation>
    <PMID>24588802</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

